STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[21] Bevacizumab for advanced cervical cancer
Sharma, Sharan
LANCET ONCOLOGY, 2014, 15 (04): : E155 - E155
[22] Bevacizumab in advanced cervical cancer
Vlachostergios, P. J.
Papandreou, C. N.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (10): : 935 - 935
[23] Bevacizumab in advanced cervical cancer
P. J. Vlachostergios
C. N. Papandreou
Clinical and Translational Oncology, 2014, 16 : 935 - 935
[24] Targeted therapy: tailoring cancer treatment
Yan, Min
Liu, Quentin Qiang
CHINESE JOURNAL OF CANCER, 2013, 32 (07) : 363 - 364
[25] TARGETED TOXIN THERAPY FOR THE TREATMENT OF CANCER
FITZGERALD, D
PASTAN, I
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (19) : 1455 - 1463
[26] Targeted therapy: tailoring cancer treatment
Min Yan
Quentin Qiang Liu
ChineseJournalofCancer, 2013, 32 (07) : 363 - 364
[27] Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab
Klein, Baruch
Gottfried, Maya
JOURNAL OF BUON, 2007, 12 : S127 - S136
[28] Advances in the treatment of metastasised cervical cancer: Is there a new standard?
Ackermann, S.
Beckmann, M. W.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2006, 66 (06) : 606 - 607
[29] Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
He, Ying
Wang, Jing
Xie, Shuangshuang
Xue, Qianlong
FRONTIERS IN SURGERY, 2022, 9
[30] The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer
Minion, Lindsey E.
Tewari, Krishnansu S.
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) : 191 - 198

← 1 2 3 4 5 →